Chang David D 4
4 · Allogene Therapeutics, Inc. · Filed Jan 28, 2025
Insider Transaction Report
Form 4
Chang David D
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to buy)
2025-01-24+1,952,130→ 1,952,130 totalExercise: $1.94Exp: 2035-01-24→ Common Stock (1,952,130 underlying) - Award
Common Stock
2025-01-24+552,174→ 5,363,240 total
Holdings
- 856,044(indirect: See footnote)
Common Stock
- 856,044(indirect: See footnote)
Common Stock
- 1,201,108(indirect: See footnote)
Common Stock
Footnotes (5)
- [F1]Includes 960 shares of the Issuer's common stock acquired by the reporting person on September 15, 2024 pursuant to an employee stock purchase program.
- [F2]Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
- [F3]Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
- [F4]Securities held in the name of the Chang 2006 Family Trust
- [F5]25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.